Enliven reports Q1 net loss of $23.6M; cash $452.4M; ELVN-001 Phase 1 data mid-2026

Enliven Therapeutics, Inc.

2026-Q1 EPS reported -$0.38

Net loss of $23.6M in Q1 2026 vs. $28.5M in Q1 2025; R&D spend $20.7M.
Cash, cash equivalents and marketable securities of $452.4M as of March 31, 2026; runway into first half of 2029.
Phase 1 data update for ELVN-001 expected mid-2026; Phase 3 ENABLE-2 initiation expected H2 2026.
ELVN-001 is a potentially best-in-class ATP-competitive BCR::ABL inhibitor for CML.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Enliven Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $23.6 million.

Period: the first quarter ended March 31, 2026
Net income: $23.6 million
Result: reported results

Exact text from the filing

Enliven reported a net loss of $23.6 million for the first quarter of 2026

View on SEC.gov

Browse all earnings releases →

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211921

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.